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Background: Adiponectin is a biomarker that is associated with type 2 diabetes and hypertension. Lower
circulating level is a risk factor. Higher levels are protective. African Americans have a higher prevalence of type 2
diabetes and hypertension and lower levels of adiponectin when compared to other racial/ethnic groups. Little is
known about the association of adiponectin on these health outcomes among African Americans. The purpose of
the study was to assess the association of adiponectin on type 2 diabetes and hypertension likelihood among
African American men and women in the Jackson Heart Study.
Methods: Separate multivariate logistic regressions were conducted stratified by sex based on cross-sectional
data with type 2 diabetes and hypertension as the outcomes. Adiponectin was divided into four quartiles with
the highest quartile as the reference. Data was collected from 2000-2004 on 3,663 participants. Data analysis was
conducted in calendar year 2014. Two- tailed P < .05 was established as level of significance.
Results: In the adjusted multivariate models, adiponectin level was inversely associated with type 2 diabetes
among women (odds ratio [OR], 95% confidence interval [CI] = 1.47, [1.02, 2.11], P = .04). There was no association
among men. Women with the lowest level of adiponectin were less likely to be hypertensive (OR, 95% CI = 0.66,
[0.46, 0.95], p = .02). There was no association among men.
Conclusion: Findings reveal differential associations between levels of adiponectin with type 2 diabetes and
hypertension likelihood among African American women. More research is needed to elucidate this differential
association.
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Obesity is a modifiable risk factor for hypertension and
type 2 diabetes. High body mass index (BMI) is a meas-
ure of obesity and is associated with an increase in blood
pressure and a greater risk of type 2 diabetes and hyper-
tension [1]. Studies have shown that adiponectin has a
profound effect on metabolism and vasculature, and is
inversely associated with type 2 diabetes and hyperten-
sion [2-4]. Lower levels of circulating adiponectin play* Correspondence: sharon.davis@nih.gov; samson.gebreab@nih.gov
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unless otherwise stated.an important role in the pathogenesis of such conditions
[5,2,3]. Circulating adiponectin levels have been shown
to be inversely associated with BMI [5]. Laboratory stud-
ies suggest that hyperadiponectinemia suppresses several
pathophysiological conditions including obesity-related
insulin resistance, endothelial dysfunction, and inflam-
mation [6]. Studies show that African Americans have
lower circulating adiponectin when compared to other
racial/ethnic groups [7]. Studies have also shown that
level of adiponectin substantially vary by lifestyle and
socioeconomic status (SES) [8,9]. Higher levels of adipo-
nectin has been shown to be protective against obesity-
related type 2 diabetes and hypertension. African
Americans have lower SES status, a higher prevalencehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lifestyle profiles when compared to other racial/ethnic
groups in the United States [10]. The majority of previ-
ous studies related to adiponectin have involved Asian
or White populations, with few studies in African
Americans [2,3,6]. Furthermore, these few studies that
included African Americans were limited by smaller
sample sizes and did not investigate the association by
gender [11,12]. Only two population-based studies with
large African American samples were identified. Using
the Atherosclerosis Risk in Communities (ARIC) study,
Duncan et al found higher adiponectin was associated
with lower incidence of types 2 diabetes in African
Americans and White participants but did not investi-
gate the association with hypertension [13]. Another
study by Wang et al found inverse association between
adiponectin and risk of hypertension in African American
postmenopausal women but the study did not include
men [12]. Many of these studies have also not made ad-
equate adjustment for important confounding factors,
such as health behaviors, biomedical factors and SES.
Therefore, investigating the association of adiponectin and
type 2 diabetes and hypertension in a large sample of
economically diverse African Americans will provide
additional insight.
Cross-sectional and case-control studies show a sig-
nificantly higher risk and incidence of type 2 diabetes
and hypertension correlated with lower levels of adipo-
nectin in African American men and women [11-13].
Few studies have assessed the differential association of
adiponectin on type 2 diabetes and hypertension within
African Americans [14-16]. The objective of this study
was to investigate the associations of adiponectin with
type 2 diabetes and hypertension in a large economically
diverse sample of African American men and women
using cross-sectional data from the Jackson Heart Study.
It is hypothesized that, after adjusting for confounders,
including SES, men and women with lower levels of adi-




The Jackson Heart Study is a single-site, prospective co-
hort study of risk factors and causes of heart disease in
adult African Americans. A probability sample of 5,301
African Americans, aged 21-94 years, residing in three
contiguous counties surrounding Jackson, Mississippi,
was recruited and examined at baseline from 2000-2004
by certified technicians according to standardized proto-
cols [17,18]. The present study includes cross-sectional
data on 3,663 participants who had complete data on all
variables of interest. The missing values included 798 for
annual household income, 496 for fasting insulin, 100for C-reactive protein (CRP), 132 for plasma leptin and
174 for circulating plasma adiponectin. The Jackson
Heart Study baseline examination included blood pres-
sure, anthropometry, survey of medical history, cardio-
vascular risk factors and collection of blood and urine
for biological variables. Written consent was obtained
from each participant at the inception of the study. The
study protocol was approved by the Institutional Review
Boards of the National Institutes of Health and the par-
ticipating Jackson Heart Study institutions – including
the University of Mississippi Medical Center, Tougaloo
College and the University of Mississippi Medical Cen-
ter. Data analysis for this study was conducted in calen-
dar year 2014.
Outcome variables
Type 2 diabetes was defined as fasting plasma glucose ≥
126 mg/dL or self-reported use of insulin or oral
hypoglycemic medications [2]. Hypertension was based
on a systolic blood pressure (SBP) of ≥ 140 mmHg, dia-
stolic blood pressure (DBP) ≥ 90 mmHg, or self-reported
medication use specifically for elevated blood pressure
[3]. Blood pressure was measured using standard proto-
cols with participant sitting quietly for 5 minutes mea-
sured at 1-minute intervals. The average of two sitting
blood pressure was used in the analysis.
Primary predictor
Adiponectin measurement was derived from venous
blood samples drawn from each participant at baseline
after more than 8 hours of fasting. Vials of serum were
stored at the Jackson Heart Study central repository in
Minneapolis, MN, at -80°C until assayed. Adiponectin
concentration was measure in 2008-2012 as total circu-
lating plasma adiponectin by an ELISA system (R&D
Systems; Minneapolis, MD) [17]. The inter-assay coeffi-
cient of variation was 8.8%. No biological degrading has
been described using stored specimens, indicating a high
validity for measurement [19].
Covariates
All covariate variables were collected at baseline and
were chosen because they are known risk factors for
type 2 diabetes and hypertension [10]. Age was derived
from date-of-birth. Socioeconomic status was based on
self-reported annual household income and divided into
three categories (≤ $19,999, $20,000 - $49,999, ≥
$50,000). Biological risk factor measures included fasting
insulin, low-density lipoprotein cholesterol (LDL), high-
density lipoprotein cholesterol (HDL), total cholesterol
(TC), homeostasis model assessment –insulin resistance
(HOMA-IR), CRPand plasma leptin. Behavioral risk fac-
tor variables included smoking status, physical activity,
alcohol status, and body mass index (BMI). Fasting
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laboratory techniques. Insulin resistance status was esti-
mated with the HOMA as insulin [20]. CRP was mea-
sured using immunoturbidimetric CRP-Latex assay from
Kamiya Biomedical Company following manufacturer’s
high-sensitivity protocol [16]. The inter-assay coeffi-
cients of variation on control samples repeated in each
assay were 4.5 and 4.4% at CRP concentration of 0.45
and 1.56 mg/dL respectively. The reliability coefficient
for masked quality-control replicates was 0.95 for the
CRP assay. Leptin was collected via venous blood sam-
ples drawn from each participant after more than 8 hours
of fasting and was analyzed with Human Leptin PIA kit
(LINCO Research, St. Charles, MI, USA) [21]. Accept-
able coefficient of variation was 10% [21]. Smoking sta-
tus was defined as current smokers and non-smokers.
Physical activity was assessed with a physical activity sur-
vey instrument comprised of 4 domains (active living,
work, home and garden, and sport and exercise indexes).
A total score was the sum of these domains with a max-
imum of 24. A higher score indicates a higher level of
total physical activity. Alcohol consumption status was
defined as “yes” if participant reported ever consuming
alcohol and “no” for those reporting never consuming
alcohol. Body mass index was based on standing height
and weight measured in lightweight clothing without
shoes or constricting garments and calculated as weight in
kilograms divided by height in meters squared (kg/m2).
Statistical analysis
All analyses were stratified by sex because of the differ-
ential levels of adiponectin between men and women
[14-16]. Descriptive analyses were performed using two
sample student t-test for continuous variables including
means for age, SBP, DBP, physical activity score, BMI,
fasting insulin, LDL, HDL, TC, HOMA-IR, fasting glu-
cose, CRP, plasma leptin, and circulating plasma adipo-
nectin. Chi-square test was used for categorical variables
including annual household income (i.e. SES), hyperten-
sion status, type 2 diabetes status, smoking status, alco-
hol consumption status, and circulating plasma
adiponectin in 4 quartiles ( 1 = ≤2.70 ug/mL, 2 = >2.70 –
≤4.2 ug/mL, 3 = >4.2 - ≤6.7 ug/mL, 4 = > 6.7 ug/mL).
Continuous variables were measured with one-way
ANOVA. Age, SES, biological and behavioral variables
were assessed according to the four quartiles of circulat-
ing plasma adiponectin by sex.
Separate logistic regression models for type 2 diabetes
and hypertension were stratified by sex. Five models
were analyzed with adiponectin as the primary predictor
with quartile 4 representing the highest level of adipo-
nectin as the reference. Model 1 included adiponectin as
the primary predictor, model 2 included age, model 3 in-
cluded biological indices, model 4 included behavioralindices, and model 5 included a fully adjusted model
with SES (≥ $50,000 as the reference).
A two-tailed level of significance was established as
P < .05. Analyses were conducted using SAS version
9.3 [22].
Results
The sex-stratified baseline characteristics are presented
in Table 1. Women were older and had a higher propor-
tion of annual household income ≤ $19,999, $20,000 -
$49,999, but a lower proportion of annual household
income ≥ $50,000 (P < .0001). There was also a signifi-
cantly higher proportion of women who were hyperten-
sive when compared to men (62% versus 58%, P = .008).
However, women had significantly lower SBP and DBP
when compared to men (P < .0001). Sixteen percent of
women had type 2 diabetes compared to 13% among
men (P = .003). A significantly higher proportion of men
were current smokers, had higher mean physical activity
score, and were current alcohol consumers when com-
pared to women (P < .0001, respectively). Women had
higher mean BMI than men (P < .0001). Women had
lower mean LDL cholesterol (P = .006), but higher HDL
cholesterol (P < .0001) and TC (P = .005). Men had lower
mean HOMA-IR, (P = .0002), CRP (P < .0001), plasma
leptin (P < .0001), and circulating plasma adiponectin
(P < .0001). There were also significantly different pro-
portional distributions between men and women across all
4 quartiles of circulating plasma adiponectin (P < .0001).
Table 2 presents the characteristics for men according
adiponectin quartiles. There is a significant difference in
age across the 4 quartiles, with quartile 4 having the
highest mean age of 58 years (P < .0001). There are also
significant differences in the levels of adiponectin by SES
with those with ≥ $50,000 having higher proportions of
men in quartile 1, 2, 3, and 4 (P < .0001). Mean SBP
across the 4 quartiles was higher among men in quartile
4 (P < .0001). Mean DBP was highest among men with
the lowest level of adiponectin, i.e. quartile 1 (P = .04).
Mean physical activity score, BMI, fasting insulin, and
LDL cholesterol were higher among men in quartile 1
than the other three quartiles (P = .007, <.0001, .006, .01,
respectively). Mean HDL cholesterol was highest among
those with the highest level of adiponectin in quartile 4
(P < .0001). Mean HOMA-IR, fasting glucose, and plasma
leptin was higher among those in quartile 1 (P < .0001,
.009, <.0001, respectively).
Table 3 presents the characteristics for women accord-
ing to the 4 quartiles of adiponectin. As revealed in
men, higher mean age for women were in quartile 4
(57 years, P < .0001). Women with higher mean SBP also
had the highest levels of adiponectin in quartile 4
(P < .0001). A higher proportion of women who had type
2 diabetes had the lowest level of adiponectin in quartile
Table 1 Characteristics of study participants (N = 3,663)
Men (N = 1,334, 36.4%) Women (N = 2,329, 63.6%) P-valuea
Age (years), mean ± stdb 53.4 ± 13.0 54.5 ± 12.7 .01
Annual household income,%
Less than $19,999 19.9 32.3 <.0001
$20,000 - 49,999 32.9 39.2
$50,000 or more 47.2 28.6
Hypertensive, % 57.7 62.1 .008
Systolic blood pressure (mmHg) 127.8 ± 18.1 125.9 ± 18.2 .002
Diastolic blood pressure (mmHg) 81.6 ± 10.4 77.5 ± 10.0 <.0001
Type 2 Diabetic, % 12.6 16.2 .003
Current Smoker,% 16.6 10.4 <.0001
Physical activity score 8.8 ± 2.6 8.3 ± 2.5 <.0001
Alcohol consumer, % 61.7 40.0 <.0001
BMIc (kg/m2) 29.8 ± 6.2 32.8 ± 7.6 <.0001
Fasting insulin (uU/mL) 17.1 ± 30.7 18.8 ± 15.5 .05
LDL-Cholesterold (mg/dL) 128.5 ± 36.6 125.1 ± 36.1 .006
HDL-Cholesterole (mg/dL) 46.0 ± 12.5 55.1 ± 14.4 <.0001
Total Cholesterol (mg/dL) 196.1 ± 39.1 199.8 ± 39.4 .005
HOMA-IRf 3.45 ± 2.42 3.78 ± 2.41 .0002
Fasting Glucose (mg/dl) 99.4 ± 31.4 99.1 ± 30.9 .78
CRPg (mg/dL) .37 ± 1.09 .59 ± .84 <.0001
Plasma leptin (ng/mL) 11.2 ± 10.6 37.5 ± 23.3 <.0001
Circulating Plasma adiponectin (ug/mL) 4.1 ± 3.3 6.0 ± 4.6 <.0001
Circulating Plasma adiponectin, %
≤2.70 ug/mL 38.8 17.5 <.0001
>2.70 - ≤4.2 ug/mL 26.8 23.8
>4.2 - ≤6.7 ug/mL 20.3 28.0
>6.7 ug/mL 14.1 30.7
aTwo sample t-test for continuous variables and chi-square for categorical variables; significance established as P < .05.
bstd = standard deviation. All continuous variables present mean ± deviation.
cBMI = body mass index.
dLDL = low-density lipoprotein.
eHDL = high-density lipoprotein.
fHOMA-IR = homeostasis model assessment – insulin resistance.
gCRP = C-reactive protein.
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insulin also had the lowest level of adiponectin in quar-
tile 1(P < .0001, <.0001, respectively). Those with higher
mean HDL cholesterol and TC had the highest level of
adiponectin in quartile 4 (P < .0001, .04, respectively).
Women with higher mean HOMA-IR, fasting glucose,
CRP, and plasma leptin have the lowest level of adipo-
nectin in quartile 1(P < .0001, .0008, <.0001, .0001).
Multivariable regression models with adiponectin on type
2 diabetes and hypertension
Table 4 reveals there were no significant associations
between adiponectin and type 2 diabetes in the crude
and multivariable models among men. Although non-significant, those with the lowest level of adiponectin
(quartile 1) had higher likelihood of having type 2
diabetes (odds ratio [OR], 95% confidence interval
[CI] = 1.12,[0.68,1.83], P = .65) in the age adjusted model.
This association attenuated and remained non-significant
in a fully adjusted model [OR, 95%CI =0.75, [0.43,1.30],
P = .30]. In the crude model, women with the lowest level
of adiponectin were associated with a higher likelihood
(67%) of having type 2 diabetes when compared to those
with the highest level of adiponectin (OR, 95%CI = 1.67,
[1.22, 2.28], P = .001). The model adjusted for age revealed
those with lowest and lower levels of adiponectin
(i.e. quartile 1 and 2) were twice and 1.42 times more
likely to have type 2 diabetes compared to women with
Table 2 Characteristics among men by circulating plasma adiponectin (N = 1,334)
Plasma Adiponectin (ug/mL)a
Q1(n = 518) Q2(n = 357) Q3(n = 271) Q4(n = 188) P –valueb
Age (years), mean ± stdc 51.07 ± 11.76 53.27 ± 13.04 54.76 ± 13.10 58.28 ± 14.61 <.0001
Annual household income,%
Less than $19,999 13.51 21.01 22.88 30.85
$20,000 - 49,999 32.82 33.33 33.58 31.38
$50,000 or more 53.67 45.66 43.54 37.77 <.0001
Hypertensive, % 55.98 56.30 57.93 64.89 .18
Systolic blood pressure (mmHg) , mean ± std 126.43 ± 15.88 127.32 ± 18.41 126.87 ± 17.25 133.64 ± 22.81 <.0001
Diastolic blood pressure (mmHg), mean ± std 82.57 ± 10.02 81.44 ± 10.39 80.59 ± 10.35 80.80 ± 11.20 .04
Type 2 Diabetic, % 12.93 11.48 11.44 15.43 .54
Current Smoker,% 15.06 16.81 16.97 19.68 .53
Physical activity score, mean ± std 8.98 ± 2.49 8.80 ± 2.67 8.77 ± 2.51 8.21 ± 2.75 .007
Alcohol consumption, % 64.67 59.38 61.99 57.45 .24
BMId (kg/m2), mean ± std 31.06 ± 6.21 29.85 ± 6.14 29.38 ± 6.17 26.76 ± 5.51 <.0001
Fasting insulin (uU/mL), mean ± std 20.71 ± 44.12 15.77 ± 11.06 14.65 ± 9.99 13.31 ± 30.31 .006
LDLe Cholesterol (mg/dL), mean ± std 131.27 ± 37.67 128.19 ± 36.35 128.50 ± 34.80 121.19 ± 35.63 .01
HDLf Cholesterol (mg/dL), mean ± std 42.13 ± 10.24 44.43 ± 10.30 48.45 ± 11.32 56.21 ± 16.79 <.0001
Total Cholesterol (mg/dL), mean ± std 5.09 ± 1.04 4.97 ± 1.00 5.03 ± 0.95 4.97 ± 0.97 .31
HOMA-IRg, mean ± std 4.17 ± 2.97 3.28 ± 1.89 3.06 ± 1.97 2.30 ± 1.39 <.0001
Fasting Glucose (mg/dL), mean ± std 102.24 ± 33.53 100.01 ± 36.59 96.52 ± 25.07 94.34 ± 20.08 .009
CRPh (mg/dL),mean ± std 0.43 ± 1.59 0.36 ± 0.63 0.32 ± 0.49 0.30 ± 0.65 .40
Plasma leptin (ng/mL), mean ± std 12.28 ± 10.77 11.06 ± 9.47 11.90 ± 12.57 7.82 ± 8.38 <.0001
aAdiponectin in quartiles (Q = quartile): 1) Q1 = ≤2.70 ug/mL, 2) Q2 = >2.70 – ≤4.2 ug/mL, 3)Q3 = >4.2 – ≤6.7 ug/mL, 4) Q4 > 6.7 ug/mL.
bOne-way ANOVA for continuous variables and chi-square for categorical variables; significance established as P < .05.
cstd = standard deviation.
dBMI = body mass index.
eLDL = low-density lipoprotein.
fHDL = high-density lipoprotein.
gHOMA-IR = homoeostasis model assessment – insulin resistance.
hCRP = C-reactive protein.
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[1.58, 3.03], [1.03, 1.95], P < .0001 and .04, respectively).
The model adjusted for biological risk factors revealed
women with the lowest level of adiponectin were 47%
more likely to have type 2 diabetes than women with the
highest level ( OR, 95% CI = 1.47, [1.02, 2.12], P = .03).
The model adjusted for behavioral risk factors similarly re-
vealed that women with the lowest and lower levels of adi-
ponectin were 2.19 and 1.41 times more likely to have
type 2 diabetes than those with the highest level (95%
CI = [1.58, 3.03], [1.03, 1.94], P < .0001 and .03, respect-
ively). The fully adjusted model with SES included reveal
women with the lowest level of adiponectin retained a
significant association with type 2 diabetes (OR, 95%
CI = 1.47, [1.02, 2.11], P = .04).
Table 5 presents the findings for the association of adi-
ponectin and hypertension. In the age-adjusted model,
men with the lowest level of adiponectin were associatedwith non-significant increase in the prevalence of hyper-
tension (OR, 95% CI = 1.07, [0.73, 1.58], P = .72). The as-
sociations remained non-significant in the subsequent
multivariate models. In the model adjusted for age,
women with the lowest and lower levels of adiponectin
(quartile 1 and 2) were significantly more likely to have
hypertension (OR, 95% CI = 1.39, 1.32 [1.05, 1.85], [1.02,
1.70], P = .02, .04, respectively). In the models adjusted
for biological and behavioral risk factors, women with
the lowest level of adiponectin were 33% less likely to be
hypertensive when compared to women with the highest
level of adiponectin (OR, 95% CI = 0.67, [0.46, 0.96],
P = .03) and 34% (OR, 95% CI = 0.67, [0.46, 0.96],
P = .03), respectively. After final adjustments for SES,
women with the lowest level of adiponectin remained
significantly less likely to be hypertensive then those
with the highest level (OR, 95% CI = 0.66, [0.46, 0.95],
P = .02).
Table 3 Characteristics among women by circulating plasma adiponectin (N = 2,329)
Plasma Adiponectin(ug/mL)a
Q1(n = 408) Q2(n = 554) Q3(n = 652) Q4(n = 715) P -valueb
Age (years), mean ± stdc 51.94 ± 12.17 52.55 ± 11.85 55.08 ± 12.74 57.10 ± 12.93 <.0001
Annual household income,%
Less than $19,999 36.03 30.32 29.75 33.85
$20,000 - 49,999 37.01 39.89 43.56 35.80
$50,000 or more 26.96 29.78 26.69 30.35 .05
Hypertensive, % 61.03 61.01 62.27 63.50 .78
Systolic blood pressure (mmHg) , mean ± std 124.48 ± 18.47 123.63 ± 15.85 126.02 ± 18.89 128.26 ± 18.82 <.0001
Diastolic blood pressure (mmHg), mean ± std 76.97 ± 9.56 77.50 ± 10.06 77.55 ± 9.70 77.65 ± 10.54 .73
Type 2 Diabetic, % 22.30 16.25 13.96 14.69 .0002
Current Smoker,% 13.73 10.65 9.51 9.09 .08
Physical activity score, mean ± std 8.52 ± 2.45 8.49 ± 2.45 8.20 ± 2.50 8.21 ± 2.60 .04
Alcohol consumption, % 40.20 43.32 38.96 38.32 .30
BMId (kg/m2), mean ± std 34.63 ± 7.37 34.01 ± 6.81 32.80 ± 7.65 30.94 ± 7.70 <.0001
Fasting insulin (uU/mL), mean ± std 26.69 ± 17.56 21.05 ± 20.03 17.42 ± 11.78 13.88 ± 10.30 <.0001
LDLe Cholesterol (mg/dL), mean ± std 124.67 ± 36.56 126.47 ± 36.39 124.91 ± 35.04 124.33 ± 36.76 .76
HDLf Cholesterol (mg/dL), mean ± std 48.01 ± 11.89 51.49 ± 11.73 55.65 ± 13.15 61.53 ± 15.90 <.0001
Total Cholesterol (mg/dL), mean ± std 5.03 ± 1.00 5.10 ± 1.01 5.12 ± 0.98 5.20 ± 1.04 .04
HOMA-IRg, mean ± std 5.28 ± 2.91 4.28 ± 2.45 3.65 ± 2.37 2.73 ± 1.40 <.0001
Fasting Glucose (mg/dL), mean ± std 103.64 ± 31.30 100.78 ± 31.50 97.22 ± 28.14 96.84 ± 32.31 .0008
CRPh (mg/dL),mean ± std 0.73 ± 0.91 0.72 ± 0.95 0.61 ± 0.85 0.40 ± 0.63 <.0001
Plasma leptin (ng/mL), mean ± std 38.64 ± 19.28 40.18 ± 20.66 37.90 ± 23.81 34.43 ± 26.47 .0001
aAdiponectin in quartiles (Q = quartile): 1) Q1 = ≤2.70 ug/mL, 2) Q2 = >2.70 – ≤4.2 ug/mL, 3)Q3 = >4.2 – ≤6.7 ug/mL, 4) Q4 > 6.7 ug/mL.
bOne-way ANOVA for continuous variables and chi-square for categorical variables; significance established as P < .05.
cstd = standard deviation.
dBMI = body mass index.
eLDL = low-density lipoprotein.
fHDL = high-density lipoprotein.
gHOMA-IR = homoeostasis model assessment – insulin resistance.
hCRP = C-reactive protein.
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This study was carried out in a large sample of
community-based middle to older aged African American
men and women. We found that lower adiponectin level
was associated with higher likelihood of having type 2 dia-
betes, but with a lower likelihood of having hypertension
in African American women. However, the associations of
adiponectin with type2 diabetes and hypertension were
less consistent in African American men.
Few studies have assessed the association of adiponec-
tin on type 2 diabetes and hypertension risk in African
Americans [11-13]. Our findings of inverse association
between adiponectin levels and type 2 diabetes among
women are consistent with several previous studies, al-
though in men this association was less consistent. For
instance, Duncan et al analysis of the effects of adipo-
nectin on risk of type 2 diabetes among a large commu-
nity based sample revealed African Americans with
lower quartiles of adiponectin had significantly higherrisk of type 2 diabetes after multiple adjustments for
confounders [13]. Hanley et al, likewise, demonstrated a
significant inverse relationship between adiponectin and
incidence of type 2 diabetes among African Americans
[11]. Conversely, a cohort study of older African
American participants showed no significant associ-
ation between level of adiponectin and incidence of
type 2 diabetes [23]. The reasons for the sex-specific
difference in the association of adiponectin with type 2
diabetes are and hypertension is unclear. However, it
may be attributable to gender differences in adiposity.
African American women in this study tend to have a
higher BMI, WC and percentage of body fat, especially
subcutaneous fat, than African American men [15]. In
addition, it is also possible sex-specific hormones, such
as estradiol and testosterone, may also explain the
sex difference in the association of adiponectin with
diabetes and hypertension in our study [24-26]. Further
research on adiponectin and type 2 diabetes and
Table 4 Association between adiponectina and type 2 diabetes using crude and adjusted logistic regression among
men and women (N = 3,663)
Men (N = 1,334) Women (N = 2,329)
Predictor Odds ratio (95% confidence interval) P-value Odds ratio (95% confidence interval) P-value
Adiponecin Q1b 0.81 (0.51, 1.31) .39 1.67 (1.22, 2.28) .001
Adiponectin Q2 0.71 (0.43, 1.19) .19 1.13 (0.83, 1.53) .44
Adiponectin Q3 0.71 (0.41, 1.22) .21 0.94 (0.69, 1.28) .70
Q4 1.0 1.0
Adiponectin Q1c 1.12 (0.68, 1.83) .65 2.19 (1.58, 3.03) <.0001
Adiponectin Q2 0.88 (0.52, 1.48) .62 1.42 (1.03, 1.95) .04
Adiponectin Q3 0.82 (0.47, 1.43) .49 1.03 (0.76, 1.41) .83
Q4 1.0 1.0
Adiponectin Q1d 0.70 (0.40, 1.21) .20 1.47 (1.02, 2.12) .03
Adiponectin Q2 0.64 (0.37, 1.12) .12 1.10 (0.79, 1.55) .58
Adiponectin Q3 0.64 (0.36, 1.14) .13 0.86 (0.62, 1.20) .38
Q4 1.0 1.0
Adiponectin Q1e 1.13 (0.69, 1.85) .63 2.19 (1.58, 3.03) <.0001
Adiponectin Q2 0.87 (0.52, 1.48) .61 1.41 (1.03, 1.94) .03
Adiponectin Q3 0.83 (0.48, 1.45) .51 1.02 (0.75, 1.39) .90
Q4 1.0 1.0
Adiponectin Q1f 0.75 (0.43, 1.30) .30 1.47 (1.02, 2.11) .04
Adiponectin Q2 0.65 (0.37, 1.14) .13 1.10 (0.78, 1.55) .58
Adiponectin Q3 0.64 (0.36, 1.16) .14 0.86 (0.62, 1.22) .36
Q4 1.0 1.0
aAdiponectin in quartiles (Q = quartile): 1) Q1 = ≤2.70 ug/mL, 2) Q2 = >2.70 – ≤4.2 ug/mL, 3)Q3 = >4.2 – ≤6.7 ug/mL, 4) Q4 > 6.7 ug/mL. The referent group is
Q4 > 6.7 ug/mL.
bModel 1, crude.
cModel 2, partly adjusted for age.
dModel 3, partly adjusted for age, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total cholesterol, c-reactive protein, plasma leptin.
eModel 4, partly adjusted for age, body mass index, smoking status, physical activity score and alcohol consumption status.
fModel 5, fully adjusted for age, body mass index, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total cholesterol, plasma leptin,
C-reactive protein, smoking status, physical activity score, alcohol consumption status and socioeconomic status based on annual household income.
A two-tailed level of significance was established as P < .05.
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mones and adiposity measures is warranted to elucidate
the biological mechanisms of this association.
Findings regarding hypertension demonstrated women
with lower quartiles of adiponectin were less likely to be
hypertensive when compared to those in the highest
quartile. Although not significant, we also observed
similar pattern in men. These ‘paradoxical’ findings be-
tween adiponectin and hypertension are inconsistent
with several previous studies that reported inverse asso-
ciation between adiponectin and hypertension [3,11,12].
For example, Wang et al reported a significant inverse
relationship between adiponectin and hypertension in
African American women [12]. Iwashima et al likewise
reported a significant association between low levels of
adiponectin and hypertension in a Japanese study popu-
lation [3]. However, other studies have also reported
similar findings [14,27-30]. One animal study in which
rats were feed a high salt diet exhibited hypertensionassociated with elevated levels of adiponectin [28]. In-
creased levels of adiponectin have been described in
hospital patients with both systolic and diastolic forms
of heart failure [29]. One of the authors in the current
population study found significant association of
increased adiponectin among hypertensives with left
ventricular mass among African Americans [14]. Simi-
larly, in the Health ABC biracial cohort, higher circulat-
ing concentrations of adiponectin were associated with
higher risk of coronary heart disease in older African
Americans, even after adjustments for known risk fac-
tors [23]. The biological underlying of such “paradoxical”
association between adiponectin and hypertension is not
clear. However, it has been suggested that the beneficial
effects of adiponectin may depend on other factors in-
volved in blood pressure regulation, such as excess diet-
ary salt intake, activation of the renin-angiotensin-
aldosterone system as well as metabolic factors [3-6]. Al-
though several studies report an inverse protective
Table 5 Association between adiponectina and hypertension using crude and adjusted logistic regression among men
and women (N = 3,663)
Men (N = 1,334) Women (N = 2,329)
Predictor Odds ratio (95% confidence interval) P-value Odds ratio (95% confidence interval) P-value
Adiponectin Q1b 0.69 (0.49, 0.97) .03 0.90 (0.70, 1.16) .41
Adiponectin Q2 0.70 (0.48, 1.00) .05 0.90 (0.72, 1.13) .36
Adiponectin Q3 0.75 (0.51, 1.10) .13 0.95 (0.76, 1.18) .64
Q4 1.0 1.0
Adiponectin Q1c 1.07 (0.73, 1.58) .72 1.39 (1.05, 1.85) .02
Adiponectin Q2 0.94 (0.63, 1.41) .76 1.32 (1.02, 1.70) .04
Adiponectin Q3 0.92 (0.60, 1.40) .68 1.13 (0.88, 1.45) .34
Q4 1.0 1.0
Adiponectin Q1d 0.79 (0.49, 1.26) .32 0.67 (0.46, 0.96) .03
Adiponectin Q2 0.75 (0.47, 1.20) .23 0.86 (0.63, 1.16) .32
Adiponectin Q3 0.85 (0.53, 1.37) .51 0.86 (0.65, 1.13) .28
Q4 1.0 1.0
Adiponectin Q1e 0.79 (0.49, 1.26) .33 0.66 (0.46, 0.95) .03
Adiponectin Q2 0.75 (0.47, 1.19) .22 0.85 (0.63, 1.16) .33
Adiponectin Q3 0.85 (0.53, 1.37) .51 0.85 (0.64, 1.13) .28
Q4 1.0 1.0
Adiponectin Q1f 0.80 (0.50, 1.28) .36 0.66 (0.46, 0.95) .02
Adiponectin Q2 0.75 (0.47, 1.20) .23 0.86 (0.63, 1.16) .32
Adiponectin Q3 0.86 (0.53, 1.38) .52 0.85 (0.64, 1.12) .25
Q4 1.0 1.0
aAdiponectin in quartiles (Q = quartile): 1) Q1 = ≤2.70 ug/mL, 2) Q2 = >2.70 – ≤4.2 ug/mL, 3)Q3 = >4.2 – ≤ 6.7 ug/mL, 4) Q4 > 6.7 ug/mL. The referent group is
Q4 > 6.7 ug/mL.
b = Model 1, crude.
c = Model 2, partly adjusted for age.
d = Model 3, partly adjusted for age, fasting insulin, HOMA-IR(Insulin resistance), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total
cholesterol, c-reactive protein, plasma leptin.
e = Model 4, partly adjusted for age, body mass index, smoking status, physical activity score, alcohol consumption status.
f = Model 5, fully adjusted for age, body mass index, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total cholesterol, plasma leptin,
fasting insulin, HOMA-IR, C-reactive protein, smoking status, physical activity score, alcohol consumption status, and socioeconomic status based on annual
household income.
A two-tailed level of significance was established as P < .05.
Davis et al. BMC Cardiovascular Disorders  (2015) 15:13 Page 8 of 10association between adiponectin levels and type 2 dia-
betes and hypertension there are other investigations
that indicate the opposite [3,5,6,11-14,23,27-30].
These discrepancies are probably due to the different
characteristics in the study populations. This study revealed
higher levels of adiponectin was protective for the probabil-
ity of type 2 diabetes and lower levels was protective for
hypertension among women. Findings differ from other
studies which show similar magnitude of association be-
tween men and women [11]. In addition, adiponectin resist-
ance has been posited to explain some of the “paradoxical”
associations of adiponectin with adverse outcomes [31,32].
Findings regarding hypertension demonstrated men and
women with lower quartiles of adiponectin were less likely
to be hypertensive when compared to those in the highest
quartile and therefore indeed may be indicative of adipo-
nectin resistance. Findings are inconsistent with otherinvestigations that showed a significant inverse association
between adiponectin and hypertension likelihood
[3,12,13,33]. However, such studies assessed one gender
and did not include both genders. Only one study com-
pared the association between White and African
Americans [13]. Adiponectin could serve as a marker of
disease severity in older adults with risk factors but not
to the same degree as younger individuals. In addition
to its protective effects, increased levels of adiponectin may
be harmful particularly among the elderly. This is demon-
strated in this study as observed among women when age
was included as a continuous variable in the models
adjusted for biological, behavioral, and SES factors.
Strengths and limitations
The strength of this investigation is that findings were
from the largest community-based sample of African
Davis et al. BMC Cardiovascular Disorders  (2015) 15:13 Page 9 of 10Americans, a cohort with strict protocol and high
quality-control. It also addresses two of the most im-
portant health outcomes that disproportionately affect
African Americans. In addition, it presents differential
findings among African American women and men re-
garding the association of adiponectin with type 2 dia-
betes and hypertension. One limitation of the study is
that findings cannot be generalizable to other ethnic
groups. Secondly, this is a cross-sectional analysis, thus,
we cannot establish causal relationships between adipo-
nectin and type 2 diabetes and hypertension. Further-
more, residual confounding may have impacted the
results. Although we adjusted for several known con-
founders, our study did not adjust for other con-
founders, such as dietary salt intake, sex hormones, and
adiposity measures. Finally, our study used total adipo-
nectin rather high molecular weight (HMW) adiponectin
, which is considered the most biologically active form.
This could also potentially affect our findings since some
studies suggested that difference in biological activity be-
tween different isoforms of adiponectin and metabolic
abnormalities [34], but another study has also demon-
strated that HMW does not provide more significant in-
formation than total adiponectin [35].
Conclusion
The major finding of this study was that after adjust-
ments for age, biology, behavior and SES, adiponectin
was inversely associated with type 2 diabetes in African
American women, but the association was less
consistency in men. Furthermore, we also found that
women with lower levels of adiponectin were less likely
to be hypertensive. More research is needed to elucidate
the differential associations of adiponectin with type 2
diabetes and hypertension among African American
women and men.
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